Multiomics integration — the simultaneous or sequential measurement and computational integration of genomics (DNA sequence variants), transcriptomics (RNA expression), proteomics (protein abundance and modification), metabolomics (small molecule metabolite profiles), epigenomics (DNA methylation, histone modification), and microbiomics (microbial community composition) from the same biological specimens — creating an unprecedented holistic view of biological system state that single-omic approaches fundamentally cannot provide and defining the scientific and commercial frontier of the Multiomics Market, with precision medicine, drug discovery, and biomarker development as the primary commercial application domains.

The reductionism limitation driving multiomics adoption — the scientific recognition that individual omics layers provide incomplete and sometimes misleading biological insight in isolation — the transcriptome-proteome correlation (mRNA levels explaining only thirty to forty percent of protein abundance variation due to post-transcriptional regulation, translation efficiency, and protein degradation rate differences) exemplifying the information loss when single omic measurements are used as proxies for biological function. Disease mechanisms frequently requiring multiomics interrogation to understand — a genomic variant creating risk through altered transcriptional regulation detected by epigenomics and transcriptomics, ultimately affecting a metabolic pathway measurable by metabolomics that creates the phenotype — with each layer providing an essential piece of the mechanistic puzzle that becomes coherent only through integration.

The Human Cell Atlas — the foundational multiomics mapping project — the international consortium using single-cell multiomics (simultaneous scRNA-seq + ATAC-seq chromatin accessibility + protein measurement) to create reference maps of every cell type in the human body across development, tissue locations, and disease states. The HCA's publication of the first comprehensive multiomics reference atlas sections (lung, gut, immune system) providing the normal reference that enables disease-associated multiomics deviations to be identified and interpreted — with pharmaceutical companies using HCA reference data to identify disease-relevant cell types and their regulatory programs as drug target discovery starting points.

Clinical multiomics — translating research discovery to patient care — the application of multiomics profiling to clinical specimens (tumor biopsies, blood, cerebrospinal fluid) for patient stratification, treatment selection, and monitoring in oncology (the most advanced clinical multiomics application), neurodegenerative disease, autoimmune conditions, and cardiovascular risk prediction. Foundation Medicine's comprehensive genomic profiling, Tempus AI's multimodal cancer data platform, and Guardant Health's liquid biopsy combined with clinical data integration representing the commercial vanguard of clinical multiomics, with emerging players adding proteomics and metabolomics layers to genomic profiling to improve predictive accuracy beyond what genomics alone achieves.

Do you think multiomics will become a routine clinical diagnostic tool across multiple disease areas within the next decade, or will data integration complexity, cost, and the absence of standardized clinical interpretation frameworks maintain multiomics as a research tool and specialized clinical application for the foreseeable future?

FAQ

What technologies are used for each layer of multiomics measurement and what are their throughput and cost characteristics? Multiomics technology platforms by layer: genomics: whole genome sequencing (WGS) — Illumina NovaSeq X, MGI DNBSEQ; cost: $200–600 per genome; whole exome sequencing (WES): $300–800; SNP arrays: $50–200 for GWAS studies; transcriptomics: bulk RNA-seq — Illumina standard; $100–300 per sample; single-cell RNA-seq (scRNA-seq) — 10x Genomics Chromium (dominant platform), Parse Biosciences, BD Rhapsody; $500–2,000 per sample (1,000–10,000 cells); spatial transcriptomics — 10x Visium, Nanostring CosMx, Vizgen MERSCOPE; $1,000–5,000 per section; epigenomics: ATAC-seq (chromatin accessibility) — $500–1,500; ChIP-seq (histone modification) — $500–1,000; WGBS (whole genome bisulfite sequencing for DNA methylation) — $500–1,000; single-cell ATAC-seq — $1,000–2,500; proteomics: mass spectrometry-based (LC-MS/MS) — $200–500 per sample (data-dependent acquisition); Olink Proximity Extension Assay — 3,000 protein panel plasma proteomics; $300–600 per sample; SomaScan (Somalogic) — 7,000 protein plasma panel; $500–1,000 per sample; metabolomics: untargeted LC-MS/MS or GC-MS — $200–500 per sample; targeted metabolomics panel — $100–300 per sample; NMR metabolomics — $100–200 per sample; microbiomics: 16S rRNA amplicon sequencing — $50–150 per sample; shotgun metagenomics — $200–500 per sample; integration platforms: cloud-based multiomics analysis — AWS, Google Cloud Life Sciences, Seven Bridges Genomics, DNAnexus; bioinformatics integration tools: MOFA+, DIABLO, MINT, Seurat WNN for single-cell multiomics.

How is multiomics being applied in pharmaceutical drug discovery and development? Multiomics in pharmaceutical R&D applications: target identification: integrating GWAS (genetic associations with disease) + eQTL (expression quantitative trait loci — genomic variants affecting gene expression) + proteomics — identifying genes and proteins causally linked to disease through genetic evidence; Mendelian randomization using multiomics data; patient stratification: tumor multiomics for clinical trial patient selection; identifying molecular subtypes within histologically similar cancers; TCGA (The Cancer Genome Atlas) multiomics enabling breast cancer PAM50 subtyping clinical application; biomarker development: blood-based multiomics biomarker panels for early disease detection (liquid biopsy multiomics), treatment response monitoring, toxicity prediction; mechanism of action (MoA) elucidation: transcriptomics + proteomics profiling of drug-treated cells versus vehicle — identifying drug MoA through pathway and network analysis; comparing with disease signatures validating on-target engagement; toxicogenomics: RNA-seq + metabolomics of drug-treated liver organoids or animal liver — early prediction of hepatotoxicity; predicting clinical toxicity from preclinical multiomics; drug combination discovery: perturbation multiomics (CRISPR screen + transcriptomics — Perturb-seq) identifying synergistic gene pairs as basis for combination therapy rational design; key pharmaceutical multiomics investments: GSK's Human Genetics department multiomics platform; Pfizer's BioNTech collaboration for mRNA + multiomics; Sanofi's Alnylam partnership using multiomics; AstraZeneca's Centre for Genomics Research multiomics platform; Novartis Institutes for BioMedical Research multiomics integration.